Mesa Laboratories, Inc. (MLAB) - 10-K Summary
Business Context and Reporting Period
Company: Mesa Laboratories, Inc.
Filing Type: Form 10-K (Annual Report)
Fiscal Year Ended: March 31, 2026
Business Overview: A global leader in life sciences tools and critical quality control solutions for pharmaceutical, healthcare, and medical device industries. Operations are organized into four segments: Sterilization and Disinfection Control, Biopharmaceutical Development, Calibration Solutions, and Clinical Genomics.
Headquarters: Lakewood, Colorado.
Key Financial Metrics (Fiscal Year 2026)
| Metric | 2026 | 2025 | Change |
|---|---|---|---|
| Total Revenues | $249.1 million | $241.0 million | +3.4% |
| Gross Profit | $158.3 million | $150.9 million | +4.9% |
| Gross Margin | 63.5% | 62.6% | +0.9 pts |
| Operating Income | $18.5 million | $16.3 million | +13.3% |
| Net Income | $6.7 million | $(2.0) million | Turnaround to Profit |
| Diluted EPS | $1.21 | $(0.36) | N/A |
| Operating Cash Flow | $42.8 million | $46.8 million | -8.5% |
| Debt Outstanding | $152.0 million | $171.2 million | -11.2% |
| Cash & Equivalents | $26.9 million | $27.3 million | -1.5% |
Note: Debt includes $84.5 million on the Revolver and $67.5 million on the Term Loan. Convertible notes were fully settled in August 2025.
Material Changes vs. Prior Period
- Revenue Growth: Driven primarily by the Sterilization and Disinfection Control segment (+8.7%) and Calibration Solutions (+3.5%). Clinical Genomics declined (-3.6%) due to macroeconomic conditions and trade tensions in China.
- Profitability: Net income turned positive ($6.7M) from a net loss ($2.0M) in 2025. This was aided by the absence of a $274.5 million goodwill impairment charge recorded in 2024 and improved gross margins.
- Operating Expenses: Increased 3.9% to $139.8 million, largely due to $6.7 million in CEO transition costs (severance and accelerated stock-based compensation) and foreign currency translation impacts.
- Debt Restructuring: The company settled $97.5 million of convertible senior notes at maturity in August 2025 using borrowings from its revolving credit facility. The credit facility spread was reduced in October 2025.
- Backlog: Decreased to $33.6 million from $43.2 million, primarily due to order timing in Clinical Genomics and normalization of fulfillments in Sterilization and Disinfection Control.
Guidance, Outlook, and Risks
- Leadership Transition: Dr. Siddhartha Kadia assumed the role of CEO effective April 2026. The company anticipates the financial impact of China-related challenges in Clinical Genomics will be substantially smaller in fiscal 2027.
- Outlook: Management expects continued execution of product development and commercial strategies in the Americas and Europe. Currency translation is expected to remain a variable factor.
- Key Risks:
- Geopolitical & Trade: Ongoing trade tensions and tariffs (particularly affecting China and Biopharmaceutical Development) impact demand and margins.
- Customer Concentration: A single customer accounts for approximately 20% of Clinical Genomics revenues.
- Regulatory: Compliance with evolving cybersecurity regulations (e.g., EU Cyber Resilience Act) and FDA requirements.
- Supply Chain: Reliance on sole or limited sources for certain materials and potential tariff increases.
Investor Verification Checklist
- China Exposure: Verify the trajectory of Clinical Genomics sales in China and the effectiveness of mitigation strategies against trade tensions.
- Debt Service: Confirm the impact of the increased revolver utilization ($84.5M outstanding) on future interest expense and liquidity, given the higher variable rates compared to the retired convertible notes.
- CEO Transition Costs: Assess whether the $6.7 million in one-time CEO transition costs impacts the comparability of operating expense trends.
- Goodwill Impairment: Monitor the Clinical Genomics reporting unit, which underwent quantitative impairment testing in 2026, for future valuation risks.
- Dividend Sustainability: Review cash flow generation relative to the quarterly dividend of $0.16 per share and debt covenants.